Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Ovarian cancer, drawn from the whole corpus: 306 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
12 medicines on record are linked to one of the types below rather than to Ovarian cancer itself. Grouped by the type that holds them; each list opens that type's own page.
No effective screening.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
PARP resistance via BRCA reversion.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Platinum-resistant disease is the hardest setting; three drugs with survival benefit arrived in 2023-26 and each adds months, so combining and sequencing them is the next step.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Screening is unsolved: the UKCTOCS trial found no mortality reduction, so three-quarters of patients are still diagnosed at stage III-IV; opportunistic salpingectomy and multi-cancer blood tests are the live routes.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Platinum resistance is eventually near-universal in high-grade serous disease, and each new drug adds months, not years.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
PARP inhibitor resistance (BRCA reversion, restored fork protection) has no approved counter; later-line PARP use has been curtailed by OS signals.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Immunotherapy fails in first-line disease; benefit is confined to PD-L1-positive platinum-resistant tumours.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Clear-cell, mucinous, and carcinosarcoma have no subtype-specific approved therapy.
FRα-low patients are excluded from mirvetuximab; next-generation ADCs are not yet approved.
Access to HRD testing, PARP inhibitors, and ADCs is limited outside high-income countries.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Optimal duration of maintenance and ctDNA-guided de-escalation are untested.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 88 changes by month →When this page itself was last checked or edited.
EMA orphan designation EU/3/26/3258 of cabazitaxel for ovarian cancer, sponsor Nadeno Nanoscience AS (the company's product PACAB-002)
FDA approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Platinum-resistant PD-L1+ ovarian cancer
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
FDA approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.